Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

40.0%

6 terminated/withdrawn out of 15 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

5 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

6(42.9%)

Phase 3

4(28.6%)

Phase 1

3(21.4%)

Phase 4

1(7.1%)

14Total

Phase 2(6)

Phase 3(4)

Phase 1(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT03133650Phase 1Active Not Recruiting

A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing

Role: collaborator

NCT04620239Phase 3Recruiting

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

Role: lead

NCT03315754Phase 2Active Not Recruiting

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Role: lead

NCT00946881Phase 1Completed

Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

Role: lead

NCT03849365Phase 4Terminated

Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer

Role: lead

NCT04017325Completed

European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up

Role: lead

NCT04225299Phase 3Withdrawn

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Role: lead

NCT01310894Phase 3Completed

Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.

Role: lead

NCT01021956Phase 2Terminated

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

Role: lead

NCT01573156Phase 1Terminated

Vascular Targeted Photodynamic Therapy T1a Renal Tumours

Role: collaborator

NCT01875393Phase 3Completed

Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer

Role: lead

NCT00707356Phase 2Completed

Study of WST11 in Patients With Localized Prostate Cancer

Role: lead

NCT00975039Phase 2Terminated

Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Role: lead

NCT00974662Phase 2Terminated

Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer

Role: lead

NCT00975429Phase 2Completed

Study Using WST11 in Patients With Localized Prostate Cancer

Role: lead

All 15 trials loaded